The 5-lipoxygenase-activating protein inhibitor, GSK2190915, attenuates the early and late responses to inhaled allergen in mild asthma

Clinical and Experimental Allergy

Volumn 43, Issue 2, 2013, Pages 177-186

  Kent, S E ^a   Boyce, M ^b   Diamant, Z ^c   Singh, D ^d   O'Connor, B J ^e   Saggu, P S ^f   Norris, V ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

^b Hammersmith Medicines Research Limited and Trio Medicines Limited   (United Kingdom)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

^e RESPIRATORY CLINICAL TRIALS LTD   (United Kingdom)

^f Betaplex   (United Kingdom)

Author keywords

5 lipoxygenase activating protein inhibitor; AM803; Bronchial allergen challenge; GSK2190915; Leukotriene; Sputum eosinophils

Indexed keywords

ALLERGEN; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CLOBETASOL PROPIONATE; FIBOFLAPON; LEUKOTRIENE B4; METHACHOLINE; METHACHOLINE CHLORIDE; PARACETAMOL; PLACEBO; SALBUTAMOL; SHORT ACTING BETA AGONIST; SODIUM CHLORIDE; STEROID; UNCLASSIFIED DRUG;

ADULT; ALLERGIC ASTHMA; ALLERGIC RHINITIS; AREA UNDER THE CURVE; ARTICLE; ASTHMA; ATTENUATION; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EARLY ASTHMATIC RESPONSE; EOSINOPHIL COUNT; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; IMMUNE RESPONSE; LATE ASTHMATIC RESPONSE; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; PRESYNCOPE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SPUTUM ANALYSIS; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

5-LIPOXYGENASE-ACTIVATING PROTEIN INHIBITORS; ADULT; ALLERGENS; ASTHMA; BRONCHIAL PROVOCATION TESTS; HUMANS; INDOLES; LEUKOTRIENE B4; MALE; PENTANOIC ACIDS; RESPIRATORY FUNCTION TESTS; SPUTUM; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84872561296     PISSN: 09547894     EISSN: 13652222     Source Type: Journal    
DOI: 10.1111/cea.12002     Document Type: Article

References (30)

1. Montuschi P, Peters-Golden ML. Leukotriene modifiers for asthma treatment. Clin Exp Allergy 2010; 40:1732-41.
2. Evans JF. The cysteinyl leukotriene (cyslt) pathway in allergic rhinitis. Allergol Int 2005; 2:187-90.
3. Lynch KR, O'Neill GP, Liu Q et al. Characterization of the human cysteinyl leukotriene CysLT1 receptor. Nature 1999; 399:789-93.
4. Gauvreau GM, Plitt JR, Baatjes A, MacGlashan DW. Expression of functional cysteinyl leukotriene receptors by human basophils. J Allergy Clin Immunol 2005; 116:80-7.
5. Di GA, Carnini C, Buccellati C et al. Cysteinyl-leukotrienes receptor activation in brain inflammatory reactions and cerebral edema formation: a role for transcellular biosynthesis of cysteinyl-leukotrienes. FASEB J 2004; 18:842-4.
6. Ohnishi H, Miyahara N, Gelfand EW. The role of leukotriene B(4) in allergic diseases. Allergol Int 2008; 57:291-8.
7. Lundeen KA, Sun B, Karlsson L, Fourie AM. Leukotriene B4 receptors BLT1 and BLT2: expression and function in human and murine mast cells. J Immunol 2006; 177:3439-47.
8. Grant GE, Rokach J, Powell WS. 5-Oxo-ETE and the OXE receptor. Prostaglandins Other Lipid Mediat 2009; 89:98-104.
9. Grzelewska-Rzymowska I, Gondorowicz K, Cieslewicz G, Rozniecki J. Course of non-specific bronchial reactivity to histamine after bronchospasm induced by allergen challenge in patients with bronchial asthma. Pneumonol Alergol Pol 1995; 63:273-80.
10. O'Byrne PM, Dolovich J, Hargreave FE. Late asthmatic responses. Am Rev Respir Dis 1987; 136:740-51.
11. Cockcroft DW. Allergen-induced increase in nonallergic airway responsiveness: a citation classic revisited. Can Respir J 2000; 7:182-7.
12. Palmqvist M, Bruce C, Sjostrand M, Arvidsson P, Lotvall J. Differential effects of fluticasone and montelukast on allergen-induced asthma. Allergy 2005; 60:65-70.
13. Singh D, Richards D, Knowles RG et al. Selective inducible nitric oxide synthase inhibition has no effect on allergen challenge in asthma. Am J Respir Crit Care Med 2007; 176:988-93.
14. Davis BE, Illamperuma C, Gauvreau GM et al. Single-dose desloratadine and montelukast and allergen-induced late airway responses. Eur Respir J 2009; 33:1302-8.
15. Diamant Z, Grootendorst DC, Veselic-Charvat M et al. The effect of montelukast (MK-0476), a cysteinyl leukotriene receptor antagonist, on allergen-induced airway responses and sputum cell counts in asthma. Clin Exp Allergy 1999; 29:42-51.
16. Hamilton AL, Watson RM, Wyile G, O'Byrne PM. Attenuation of early and late phase allergen-induced bronchoconstriction in asthmatic subjects by a 5-lipoxygenase activating protein antagonist, BAYx 1005. Thorax 1997; 52:348-54.
17. Diamant Z, Timmers MC, van d V et al. The effect of MK-0591, a novel 5-lipoxygenase activating protein inhibitor, on leukotriene biosynthesis and allergen-induced airway responses in asthmatic subjects in vivo. J Allergy Clin Immunol 1995; 95:42-51.
18. Hui KP, Taylor IK, Taylor GW et al. Effect of a 5-lipoxygenase inhibitor on leukotriene generation and airway responses after allergen challenge in asthmatic patients. Thorax 1991; 46:184-9.
19. Nasser SM, Bell GS, Hawksworth RJ et al. Effect of the 5-lipoxygenase inhibitor ZD2138 on allergen-induced early and late asthmatic responses. Thorax 1994; 49:743-8.
20. Evans DJ, Barnes PJ, Spaethe SM, van Alstyne EL, Mitchell MI, O'Connor BJ. Effect of a leukotriene B4 receptor antagonist, LY293111, on allergen induced responses in asthma. Thorax 1996; 51:1178-84.
21. Lorrain DS, Bain G, Correa LD et al. Pharmacology of AM803, a novel selective five-lipoxygenase-activating protein (FLAP) inhibitor in rodent models of acute inflammation. Eur J Pharmacol 2010; 640:211-8.
22. Stock N. Discovery of AM103 and AM803 potent 5 lipoxygenase-activating protein (FLAP) inhibiotrs for the treatment of asthma. Paper presented at: International Chemical Congress of the Pacific Basin Societies (Pacifichem) 2010, December 15-20; Honolulu, Hawaii, USA.2010.
23. ICH Harmonised Tripartite Guideline. Guideline for Good Clinical Practice E6(R1). 6-10-1996.
24. T Hansell, E Erin, P Barnes. The allergen challenge. Clin Exp Allergy 2002; 32:162-7.
25. Ramsmussen J. Late airways response increases at repeat allergen challenge. Allergy 1991; 46:419-26.
26. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl 1993; 16:5-40.
27. Evans JF, Bain G, Hutchinson JH, Prasit P, Lorrain DS. 5-Lipoxygenase-activating Protein (FLAP) Inhibitors Are Superior To 5-lipoxygenase (5-LO) Inhibitors For Inhibition Of Leukotriene Synthesis In Rat Lung. Am J Respir Crit Care Med 2010; 181:A4248.
28. Leigh R, Vethanayagam D, Yoshida M et al. Effects of montelukast and budesonide on airway responses and airway inflammation in asthma. Am J Respir Crit Care Med 2002; 166:1212-7.
29. Chapman KR. The efficacy of an oral inhibitor of leukotriene synthesis (MK-0591). In: Asthmatics treated with inhaled steroids. Friedman BS, ed. Am J Respir Crit Care Med 1994; 149: A215.
30. Storms W, Friedman BS, Zhang J. Treating asthma by blocking the lipoxygenase pathway. Am J Respir Crit Care Med 1995; 151:A377.